MTX2

MTX2 (Metaxin-2) is an outer mitochondrial membrane protein that maintains mitochondrial network integrity, cristae architecture, and oxidative metabolism, and whose loss propagates to nuclear morphology defects, cellular senescence, and altered cell death (PMID:32917887). It functions through distinct structural modules: an N-terminal domain that binds and stabilizes Metaxin-1 (MTX1) (PMID:34584540), and a TOM37 domain that directly engages PKM2 to promote its tetramerization and sustain glycolytic flux, with loss of MTX2 leaving the less-active dimeric PKM2 to accumulate (PMID:40585998). MTX2 deficiency disrupts the Sam50-CHCHD3-Mitofilin (MIB) axis governing cristae morphology, impairs respiratory complex I and III activity, and elevates ROS, producing tissue dysfunction in podocytes and cardiomyocytes (PMID:38250156, PMID:40585998). MTX2 abundance is set by opposing ubiquitin signals: the E3 ligase AREL1 ubiquitinates its C-terminal domain to drive degradation (PMID:34584540), while the deubiquitinase USP10 removes K48-linked chains at K93 to stabilize the protein, thereby preserving mitochondrial integrity and preventing mtDNA release and cGAS-STING activation (PMID:41705350). Together with MTX1, MTX2 enhances TNF-induced necroptosis, an activity restrained by AREL1-mediated ubiquitination (PMID:34584540). Beyond mitochondrial homeostasis, the C-terminal GST-like domain is essential for craniofacial morphogenesis (PMID:40967033), and MTX2 function is conserved across vertebrate and invertebrate models, supporting beta-barrel protein biogenesis and tissue development [PMID:bio_10.1101_2025.05.22.655489, PMID:39462037].

1. 2020 High

   Established MTX2 as essential for mitochondrial composition and function and linked its loss to nuclear morphology defects, defining a human disease-relevant role.

   Evidence Patient-derived null fibroblasts with OXPHOS, morphology, apoptosis, senescence, and mitophagy assays plus C. elegans mtx-2 depletion

   PMID:32917887

   Open questions at the time

   • Molecular mechanism linking mitochondrial defects to nuclear morphology unresolved
   • How MTX2 loss destabilizes MTX1 not mechanistically defined at this stage
2. 2021 Medium

   Defined MTX2 domain architecture functionally (N-terminal binds MTX1, C-terminal binds AREL1) and showed ubiquitin-mediated control of an MTX2/MTX1 necroptotic activity.

   Evidence Reciprocal domain-mapping Co-IP, AREL1 catalytic mutant (C790A), knockdown, and necroptosis assays

   PMID:34584540

   Open questions at the time

   • Single-lab data without reciprocal in vivo validation
   • Ubiquitination site not mapped here
   • Mechanism by which MTX2/MTX1 promote necroptosis unclear
3. 2024 High

   Connected MTX2 to the MIB cristae-organizing complex, showing it sustains Sam50-CHCHD3-Mitofilin levels and respiratory complex activity in an organ-specific (podocyte) context.

   Evidence Podocyte-specific Mtx2 knockout mice with in vitro overexpression rescue, complex activity and ROS assays

   PMID:38250156

   Open questions at the time

   • Whether MTX2 directly binds MIB components or acts indirectly not established
   • Generalizability beyond podocytes not addressed here
4. 2024 Medium

   Validated an invertebrate model recapitulating MTX2 mitochondrial and developmental phenotypes and implicated aging, TOR, and WNT signaling transcriptional programs.

   Evidence C. elegans mtx-2 mutant/RNAi with AFM, transcriptomics, and oxygen consumption analysis

   PMID:39462037

   Open questions at the time

   • Causal link between mitochondrial defects and TOR/WNT perturbation not dissected
   • Cuticle phenotype mechanism unknown
5. 2025 High

   Identified a direct TOM37-domain interaction with PKM2 driving its tetramerization, providing a mechanism by which MTX2 couples to glycolytic flux and cardioprotection.

   Evidence Cardiomyocyte-specific Mtx2 KO/OE mice, Co-IP, Seahorse flux, mass spectrometry, and TEPP-46 pharmacological rescue

   PMID:40585998

   Open questions at the time

   • Structural basis of TOM37-PKM2 binding not determined
   • Whether PKM2 regulation occurs at the mitochondrial surface or elsewhere unclear
6. 2025 Medium

   Assigned a developmental morphogenesis function to the C-terminal GST-like domain, separating it from the N-terminal domain by domain-deletion rescue.

   Evidence Xenopus morpholino knockdown with domain-deletion rescue and neural crest/chondrogenic marker analysis

   PMID:40967033

   Open questions at the time

   • Molecular partners of the C-terminal domain in craniofacial tissue unidentified
   • Whether craniofacial role is mitochondrial or independent unresolved
7. 2025 Medium

   Demonstrated cross-species functional conservation and a role in beta-barrel protein biogenesis with stage-specific regulation in muscle.

   Evidence Drosophila null mutants rescued by human MTX2, tissue-specific KO, myofibril and mitochondrial assays (preprint)

   PMID:bio_10.1101_2025.05.22.655489

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Basis for pupal- vs larval-stage specificity not defined
   • Direct beta-barrel substrate set not identified
8. 2026 High

   Identified the deubiquitinase USP10 acting at K93 to stabilize MTX2, linking MTX2 abundance to suppression of mtDNA-driven cGAS-STING inflammation.

   Evidence IP-mass spectrometry, K93R mutagenesis, ubiquitination assays, neonatal cardiomyocytes, and genetically engineered mice

   PMID:41705350

   Open questions at the time

   • How mtDNA release is gated by MTX2 mechanistically unresolved
   • Interplay between USP10 and AREL1 in setting MTX2 levels not directly tested

• How MTX2's mitochondrial scaffolding role mechanistically integrates with its surface metabolic (PKM2) and developmental (craniofacial) functions, and how ubiquitin turnover is coordinated across these contexts, remains unresolved.
• No structural model of MTX2 domain interactions
• Unclear whether developmental and metabolic roles share a common molecular mechanism
• Direct beta-barrel biogenesis substrates not enumerated